Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC
29 Juin 2023 - 1:00PM
Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today
announced that the United States Patent and Trademark Office
granted a patent claiming methods of combining vaccine-enhanced
adoptive T cell therapy with oncolytic virus adjunct therapy.
The patent has been exclusively licensed to
V2ACT Therapeutics, LLC, a joint venture between Genelux and TVAX
that was established for the purpose of developing and testing
V2ACT Immunotherapy. The patent expiry, prior to any patent term
extension, will be in 2036 and will add substantial intellectual
property protection for V2ACT Immunotherapy.
The rationale for V2ACT Immunotherapy stems from
compelling scientific evidence that vaccination generates an immune
response which increases the number of neoantigen-specific T cells
in the body and that Olvi-Vec induces an acute inflammatory
response that increases cancer tissue receptivity for the clinical
effects of adoptively transferred neoantigen-specific effector T
cells. This generates compelling support for the view that V2ACT
Immunotherapy may safely achieve superior efficacies against a wide
range of cancers.
V2ACT capitalizes on the lead assets of both
Genelux and TVAX as a combination therapy. Olvi-Vec has
demonstrated systemic immunomodulation, an excellent safety
profile, powerful immune modulation of the cancer microenvironment
and well-documented anti-cancer effects over a wide range of
cancers both in preclinical and Phase 2 clinical trials. TVAX
Immunotherapy provides a unique neoantigen-specific adoptive T cell
therapy, with an excellent safety profile and powerful anti-cancer
effects on a wide range of cancers demonstrated in preclinical and
Phase 2 clinical trials.
“We believe a strong intellectual property
portfolio, supported by this issued patent, further validates our
assessment of the clinical and commercial potential of combining
Olvi-Vec and TVAX Immunotherapy to treat patients who are
under-served by current modalities,” said Thomas Zindrick,
President, CEO and Chairman of Genelux.
“TVAX Biomedical is very excited to work with
Genelux in the V2ACT joint venture. We believe there is tremendous
scientific and clinical synergy that is affirmed by the granting of
this patent,” said Wayne Carter, President and CEO of TVAX
Biomedical.
About Genelux Corporation
Genelux is a late clinical-stage
biopharmaceutical company focused on developing a pipeline of
next-generation oncolytic viral immunotherapies for patients
suffering from aggressive and/or difficult-to-treat solid tumor
types. The Company's most advanced product candidate, Olvi-Vec
(olvimulogene nanivacirepvec), is a proprietary, modified strain of
the vaccinia virus (VACV), a stable DNA virus with a large
engineering capacity. Olvi-Vec currently is being evaluated in
OnPrime, a multi-center, randomized, open-label Phase 3
registrational trial evaluating the efficacy and safety of Olvi-Vec
in patients with platinum-resistant/refractory ovarian cancer. The
core of Genelux' discovery and development efforts revolves around
the company's proprietary CHOICE™ platform from which the Company
has developed an extensive library of isolated and engineered
oncolytic vaccinia virus immunotherapeutic product candidates,
including Olvi-Vec. For more information please visit
www.genelux.com.
About TVAX Biomedical, Inc.
TVAX Biomedical likewise is a late
clinical-stage biopharmaceutical company focused on developing
next-generation T cell immunotherapies for patients suffering from
aggressive and/or difficult-to-treat solid cancers. TVAX
Immunotherapy, the company’s proprietary therapy, offers the
promise of significantly improved clinical outcomes with low
toxicity. TVAX Immunotherapy has the potential to fundamentally
change the way immunotherapy is used to treat cancer. TVAX’s most
advanced product candidate, TVI-Brain-1, is currently being
evaluated in a multi-center, randomized, open-label Phase 2b/3
registrational trial evaluating the efficacy and safety of
TVI-Brain-1 in patients with newly diagnosed MGMT unmethylated
glioblastoma patients. TVAX received Fast Track designation for
this ground-breaking clinical trial. Unlike other forms of
immunotherapy that are effective against a limited number of cancer
types, TVAX Immunotherapy has demonstrated the potential to
effectively treat a wide range of cancers. The power of T cells is
their demonstrated ability to kill cancer cells, including cancer
stem cells, and cause significant numbers of objective clinical
responses in treated patients. For more information visit:
www.tvaxbiomedical.com.
Forward-Looking Statements
This release contains “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. “Forward-looking statements”
describe future expectations, plans, results, or strategies and are
generally preceded by words such as “believes,” “anticipates,”
“expect,” “may,” “plan” or “will”. Forward-looking statements in
this release include, but are not limited to, statements related to
the potential for V2ACT Immunotherapy to safely achieve superior
efficacies against a wide range of cancers, the potential of
combining Olvi-Vec and TVAX Immunotherapy to treat patients who are
under-served by current modalities, the extent of intellectual
property protection provided by this new patent, and the ability of
V2ACT Therapeutics, LLC to develop, test and commercialize V2ACT
Immunotherapy. Such statements are subject to a multitude of risks
and uncertainties that could cause future circumstances, events, or
results to differ materially from those projected in the
forward-looking statements. These and other risks are identified
under the caption “Risk Factors” in Genelux’ filings with the
Securities and Exchange Commission. All forward-looking statements
contained in this press release speak only as of the date on which
they were made and are based on management’s assumptions and
estimates as of such date. Genelux does not undertake any
obligation to publicly update any forward-looking statements,
whether as a result of the receipt of new information, the
occurrence of future events or otherwise.
Investor and Media Contacts
Ankit Bhargava, MDAllele Communications,
LLC815.721.4912
Source: Genelux Corporation
Genelux (NASDAQ:GNLX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Genelux (NASDAQ:GNLX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024